



For reauthorization :

1. Documentation in chart notes must demonstrate clinically meaningful LDL reduction compared to pre-treatment baseline.

If all the above requirements are met , the medication will be approved for an additional 12 months.

## References:

1. Leqvio [prescribing information]. Novartis Pharmaceuticals Corporation; 2023.
2. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020;382(16):1520-1530. doi:10.1056/NEJMoa1913805
3. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. *N Engl J Med*. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387
4. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. *J Am Heart Assoc*. 2019;8(24):e013225. doi:10.1161/JAHA.119.013225
5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. *JACC*. 2018;73(24):doi:10.1016/j.jacc.2018.11.002.
6. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in *J Am Coll Cardiol*. 2023 Jan 3;81(1):104]. *J Am Coll Cardiol*. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006
7. Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease. *Vasc Health Risk Manag*. 2023;19:421-431. Published 2023 Jul 6. doi:10.2147/VHRM.S338424

Effective date: 01/01/2024

Revised date: 07/28/2023